CA2523508A1 — Galectin 9-inducing factors
Assigned to Galpharma Co Ltd · Expires 2004-11-11 · 22y expired
What this patent protects
Galectin 9, which is a physiologically active substance showing an activity as lectin, is expressed in various cells and a correlationship is observed between the expression dose of galectin 9 and tumor metastasis ability. Namely, it is assumed that galectin 9 would relate to va…
USPTO Abstract
Galectin 9, which is a physiologically active substance showing an activity as lectin, is expressed in various cells and a correlationship is observed between the expression dose of galectin 9 and tumor metastasis ability. Namely, it is assumed that galectin 9 would relate to various physiological phenomena. Thus, a substance enabling the control of the production and release of galectin 9 is expected as exerting an antitumor activity, an activity of inducing antiinflammatory effect, etc. Therefore, it is required to clarify the same. It is found out that ~a galectin 9-inducing factor~ inducing the production and release of galectin 9 is contained in a certain solubilized tumor cell membrane fraction. This factor can be obtained as a concentrated active fraction with the use of fractionation by concanavalin A-adsorption, Resource QTM ion exchange column, hydroxyapatite column, etc. By using the activity of inducing galectin 9 of this factor, assay reagents, drugs, assays, etc. can be developed.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.